Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy

Raffaele De Caterina, Bernd Brüggenjürgen, Harald Darius, Sabine Köhler, Markus Lucerna, Ladislav Pecen, Giulia Renda, Richard John Schilling, Tessa Schliephacke, José Luis Zamorano, Jean Yves Le Heuzey, Paulus Kirchhof

Research output: Contribution to journalArticlepeer-review

23 Citations (Scopus)

Abstract

Background: Non-vitamin K antagonist oral anticoagulants (NOACs) are being introduced for stroke prevention in non-valvular Atrial Fibrillation (AF), and promise to be accepted better than Vitamin K Antagonists (VKAs) by patients, improving their Quality of Life (QoL). Aim: To assess to what extent patient-related factors influence decisions to switch from a VKA to a NOAC. Methods: The PREFER in AF Registry collected data at baseline in 2012 — at the beginning of NOAC prescriptions — and at 1-year follow-up, in 6412 patients in seven Western European countries. QoL and patient satisfaction questionnaires (EQ-5D-5L and/or PACT-Q2) were completed in 3777 patients at both visits. Data were compared across categories of patients on stable treatment with a VKA (i.e. continuously over the previous 12 months) (n = 2102) or recently switched (within 12 months) from a VKA to a NOAC (n = 213) during a 1-year follow-up, allowing a snapshot of factors influencing the switch at a time when NOACs were being introduced into the market. Results: Compared to patients on stable treatment with a VKA, switched patients were similar in terms of age, sex, body mass index and other risk factors, but had lower prevalences of hypertension and heart valve dysfunction, and a lower rate of use of concomitant treatment with antiplatelet/anti-inflammatory agents; they also had a lower CHA2DS2-VASc score. Among 25 features investigated, switched patients more often reported bruising or bleeding, complained about bruising, were dissatisfied with the anticoagulant treatment, and reported mobility problems and anxiety/depressive traits. Conclusions: At the beginning of NOAC prescriptions, European doctors tended to switch from VKAs to NOACs those patients at lower risk than “non-switchers”. Complaints about bruising or bleeding, dissatisfaction with treatment, mobility problems and anxiety/depression traits appear to be related to — and may have influenced — the choice to switch from a VKA to a NOAC.

Original languageEnglish
Pages (from-to)74-84
Number of pages11
JournalArchives of Cardiovascular Diseases
Volume111
Issue number2
DOIs
Publication statusPublished - Feb 2018

Keywords

  • Atrial fibrillation
  • Non-vitamin K antagonist oral anticoagulants
  • Patient satisfaction
  • Quality of life
  • Switching
  • Vitamin K antagonists

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy'. Together they form a unique fingerprint.

Cite this